Abstract
In December 2005, abatacept (Orencia; Bristol-Myers Squibb), a fusion protein that selectively modulates a costimulatory signal necessary for T-cell activation, was approved by the US FDA for the treatment of patients with rheumatoid arthritis who have had an inadequate response to other drugs. It is the first selective costimulation modulator to be approved.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies
Bone Marrow Transplantation Open Access 14 August 2023
-
Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
Bone Marrow Transplantation Open Access 14 August 2023
-
ANCA-Associated Vasculitic Neuropathies: A Review
Neurology and Therapy Open Access 19 January 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473–488 (2003).
Reiser H. & Stadecker, M. J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N. Engl. J. Med. 335, 1369–1377 (1996).
Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561–569 (1991).
Linsley, P. S. et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792–795 (1992).
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/125118lbl.pdf> (2005).
Webb, L. M., Walmsley, M. J. & Feldmann, M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26, 2320–2328 (1996).
Moreland, L. W. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470–1479 (2002).
Kremer J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907–1915 (2003).
Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005).
Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594–1602 (2000).
Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363, 675–681 (2004).
Breedveld, F. C. et al. The PREMIER Study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moreland, L., Bate, G. & Kirkpatrick, P. Abatacept. Nat Rev Drug Discov 5, 185–186 (2006). https://doi.org/10.1038/nrd1989
Issue Date:
DOI: https://doi.org/10.1038/nrd1989
This article is cited by
-
Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies
Bone Marrow Transplantation (2023)
-
Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
Bone Marrow Transplantation (2023)
-
Alopecia Areata: Current Treatments and New Directions
American Journal of Clinical Dermatology (2023)
-
ANCA-Associated Vasculitic Neuropathies: A Review
Neurology and Therapy (2022)
-
Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
Immunologic Research (2022)